Relmada Therapeutics to Present at the 2014 BIO International Convention CEO to Provide Highlights on the Company Drug Pipeline and Recent Corporate Developments
NEW YORK, June 19, 2014 /PRNewswire/ -- Relmada Therapeutics, which currently conducts its operations through Camp Nine, Inc. (the "Company"), (OTCBB: CMPE), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that Sergio Traversa, Chief Executive Officer, will be presenting at the 2014 BIO International Convention on Thursday, June 26, at 9:30 AM. PDT. The presentation will take place in the Solana Beach room. Hosted by the Biotechnology Industry Organization (BIO), this year's global event for biotechnology will take place June 23-26 at the San Diego Convention Center in San Diego, California.
About Relmada Therapeutics/Camp Nine, Inc.
The Company, through its majority owned subsidiary Relmada, is a clinical stage, public specialty pharmaceutical company, focused on developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at different stages of development and a deep early stage pipeline. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team with inputs from a world-class scientific advisory board. The Company's approach is expected to reduce overall clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.
The Company is currently developing LevoCap ER, its abuse resistant, once--a-day sustained release dosage form of the opioid analgesic levorphanol; d-methadone, the NDMA receptor antagonist for neuropathic pain; BuTab ER, its oral dosage form of the opioid analgesic buprenorphine and MepiGel, its FDA Orphan Drug designated topical formulation of the local anesthetic mepivacaine.
About the BIO International Convention
The BIO International Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. The Convention also features the BIO Business Forum, a unique platform for biotechnology and pharmaceutical companies, academic research institutions, and investors from around the world to gather and discuss strategic opportunities. For registration, conference agenda and exhibitor information, visit http://www.convention.bio.org/.
Forward-Looking Statement for Relmada/Camp Nine, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements.
The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Camp Nine undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information
SOURCE Relmada Therapeutics Inc.